# EVOKEN Completes Nearly $300 Million Series B+ Financing

- Category: Flash (快讯)
- Published: 2026-06-18T11:58:00.000Z
- Source date: 2026-06-18
- HTML: https://www.88z.ai/en/news/flash-20260618-8b3947ecdf03b79b
- Markdown: https://www.88z.ai/en/news/flash-20260618-8b3947ecdf03b79b.md
- Other language: https://www.88z.ai/news/flash-20260618-8b3947ecdf03b79b.md

EVOKEN has completed a Series B+ financing round of nearly $300 million, reaching a post-money valuation exceeding $2 billion. The round was co-led by Granite Asia and Shunwei Capital, with continued participation from existing shareholders such as Gaorong Ventures and Ant Group. The company operates three major platforms: LibLibAI, LibTV, and Xingliu. AI video platform LibTV saw revenue grow more than 13-fold in its first two months, contributing to a year-over-year group revenue increase of ov

## At a glance

- Completed nearly $300 million Series B+ financing with valuation over $2 billion
- LibTV revenue grew over 13-fold in two months; group revenue up over 3000% YoY in May

## The update

EVOKEN has officially completed a Series B+ financing round of nearly $300 million, with a post-money valuation exceeding $2 billion. The investment was co-led by Granite Asia and Shunwei Capital, while existing shareholders including Gaorong Ventures and Ant Group continued to increase their stakes. EVOKEN has built a product matrix comprising LibLibAI, LibTV, and Xingliu. Notably, its AI video platform, LibTV, achieved revenue growth of more than 13-fold within just two months of launch. This strong performance drove a year-over-year increase of over 3000% in the group's total revenue for May. The company plans to allocate the newly raised funds primarily toward enhancing research and development efforts and accelerating expansion into global markets to strengthen its competitive position in the AI sector.

## Sources

- [演语 EVOKEN](https://mp.weixin.qq.com/s/q43uBzL5GISBl5ItrgeUMQ) (2026-06-18)

This article is an AI-assisted synthesis by 88Z AI based on the public sources below. Product claims and availability are attributed to their publishers. It does not represent independent testing or first-hand reporting.